RxDoctor Payments Data

Constance Hall

Family · Pinehurst, NCNPI 1679046320

Payments from drug & device makers

$7,296in general payments, 2019–2025

Across 256 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$984
  • AbbVie$589
  • Phathom Pharmaceuticals, Inc.$435
  • Idorsia Pharmaceuticals US Inc$369
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$7,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,296 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,520
Medicare patients
122
Services billed
1,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$76,417
RybelsusSemaglutide16$22,118
EliquisApixaban18$20,652
VraylarCariprazine Hcl13$16,699
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,240
FarxigaDapagliflozin Propanediol12$13,999
XareltoRivaroxaban11$9,341
Atorvastatin Calcium132$1,768
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$960
Lidocaine11$874
Albuterol Sulfate HfaAlbuterol Sulfate32$817
Metoprolol Succinate56$790
Omeprazole44$743
Amlodipine Besylate117$718
Tamsulosin Hcl31$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$984$76,41765 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,831$28,23935 claims
Novo NordiskRybelsus$1,038$22,11816 claims
PfizerEliquis$94$20,65218 claims
AbbVieVraylar$589$16,69913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →